PRANAY TANWAR

Dr. PRANAY TANWAR

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Mutation Research - Reviews in Mutation Research
Verified
Journal Article
Closed access
RAVI MEHROTRARAVI MEHROTRA
RAVI MEHROTRA
STSonam Tulsyan
Sonam Tulsyan
Showket HussainShowket Hussain
Showket Hussain
BMBalraj Mittal
Balraj Mittal
SSSundeep Singh Saluja
Sundeep Singh Saluja
GRG.K. Rath
G.K. Rath

1 February 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Harsh GoelHarsh Goel
Harsh Goel
RKRahul Kumar
Rahul Kumar
PTPRANAY TANWAR
PRANAY TANWAR
Tarun Kumar UpadhyayTarun Kumar Upadhyay
Tarun Kumar Upadhyay
FKFahad Khan
Fahad Khan
Mohd SaeedMohd Saeed
Mohd Saeed
Leukemia is a heterogeneous group of hematological malignancies distinguished by differentiation blockage and uncontrolled proliferation of myeloid or lymphoid progenitor cells in the bone marrow (BM) and peripheral blood (PB). There are various types of leukemia in which intensive chemotherapy regimens or hematopoietic stem cell transplantation (HSCT) are now the most common treatments associated with severe side effects and multi-drug resistance in leukemia cells. Therefore, it is crucial to develop novel therapeutic approaches with adequate therapeutic efficacy and selectively eliminate leukemic cells to improve the consequences of leukemia. Medicinal plants have been utilized for ages to treat multiple disorders due to their diverse bioactive compounds. Plant-derived products have been used as therapeutic medication to prevent and treat many types of cancer. Over the last two decades, 50 % of all anticancer drugs approved worldwide are from natural products and their derivatives. Therefore this study aims to review natural products such as polyphenols, alkaloids, terpenoids, nitrogen-containing, and organosulfur compounds as antileukemic agents. Current investigations have identified natural products efficiently destroy leukemia cells through diverse mechanisms of action by inhibiting proliferation, reactive oxygen species production, inducing cell cycle arrest, and apoptosis in both in vitro, in vivo, and clinical studies. Current investigations have identified natural products as suitable promising chemotherapeutic and chemopreventive agents. It played an essential role in drug development and emerged as a possible source of biologically active metabolites for therapeutic interventions, especially in leukemia. DATA AVAILABILITY: Data will be made available on request.

17 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
BBBanashree Bondhopadhyay
Banashree Bondhopadhyay
SSSandeep Sisodiya
Sandeep Sisodiya
Faisal A AlzahraniFaisal A Alzahrani
Faisal A Alzahrani
MBMuhammed Bakhrebah
Muhammed Bakhrebah
Atul ChikaraAtul Chikara
Atul Chikara
Showket HussainShowket Hussain
Showket Hussain
Despite the recent advancements in therapeutics and personalized medicine, breast cancer remains one of the most lethal cancers among women. The prognostic and diagnostic aids mainly include assessment of tumor tissues with conventional methods towards better therapeutic strategies. However, current era of gene-based research may influence the treatment outcome particularly as an adjunct to diagnostics by exploring the role of non-invasive liquid biopsies or circulating markers. The characterization of tumor milieu for physiological fluids has been central to identifying the role of exosomes or small extracellular vesicles (sEVs). These exosomes provide necessary communication between tumor cells in the tumor microenvironment (TME). The manipulation of exosomes in TME may provide promising diagnostic/therapeutic strategies, particularly in triple-negative breast cancer patients. This review has described and highlighted the role of exosomes in breast carcinogenesis and how they could be used or targeted by recent immunotherapeutics to achieve promising intervention strategies.

14 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AKAsiya Khan
Asiya Khan
SSSandeep Sisodiya
Sandeep Sisodiya
MAMehreen Aftab
Mehreen Aftab
PTPRANAY TANWAR
PRANAY TANWAR
Showket HussainShowket Hussain
Showket Hussain
VGVivek Gupta
Vivek Gupta
Background: As per recent scenarios, drug resistance is a significant challenge in treating breast cancer for several reasons, such as genetic mutations, altered signaling pathways, and tumor microenvironment. Endocrine resistance is one of the biggest significant barriers to treatment, particularly in hormone receptor-positive (HR+) breast cancers, which depends on estrogen or progesterone signaling for growth. While therapies such as tamoxifen, aromatase inhibitors, and selective estrogen receptor degraders (SERDs) have effectively targeted these pathways, many patients develop resistance, rendering them less effective over time, which is driving a need for innovative therapeutics to treat breast cancer and overcome drug resistance and better treatment outcomes. Recent studies suggest that combining the different therapies, including immunotherapy, targeted therapy, chemotherapy, etc., with endocrine therapy, may bypass the endocrine resistance. Methodology: We conducted a comprehensive systematic review and meta-analysis examining the molecular mechanisms of endocrine resistance and evaluating randomized clinical trial outcomes, overall survival and progression-free survival in endocrine-resistant breast cancer patients treated with endocrine therapy, targeted therapy, immunotherapy, or chemotherapy. Results: We have analyzed 35 randomized clinical trial studies for different therapies along with combination therapy, and our results demonstrated that supplementary or additional therapies in endocrine resistance breast cancer patients have better progression-free and overall survival. Conclusions: The current study has demonstrated that combination therapies may have good survival results and patient outcomes in endocrine resistance. Also, This review sheds light on current challenges in drug resistance and the future direction of cancer treatment through a comprehensive analysis of these emerging treatment approaches to improve patient outcomes.

15 October 2021
Verified
Closed access
HGHarsh Goel
Harsh Goel
EREkta Rahul
Ekta Rahul
IGIshan Gupta
Ishan Gupta
ACAnita Chopra
Anita Chopra
ARAmar Ranjan
Amar Ranjan
PTPRANAY TANWAR
PRANAY TANWAR

15 March 2021 in Obstetrics & Gynecology Science
Verified
Journal Article
Open access
PDF file
Harsh GoelHarsh Goel
Harsh Goel
IGIshan Gupta
Ishan Gupta
MMMeenakshi Mourya
Meenakshi Mourya
SGSukhdeep Gill
Sukhdeep Gill
ACAnita Chopra
Anita Chopra
PTPRANAY TANWAR
PRANAY TANWAR
The coronavirus disease 2019 (COVID-19) has spread worldwide. It is still a pandemic and poses major health problem across the globe. In our review, clinical characteristics and laboratory parameters of COVID-19 patients were compiled systematically, with special reference to pregnant women in order to understand the disease course. An extensive literature search on various scientific databases for relevant manuscripts was conducted, which yielded 7 manuscripts for final analysis. The most common symptoms were fever (85%), cough (70.63%), chest tightness (37.36%), expectoration (33.27%), fatigue (32%), dyspnea (31.95%), and shortness of breath (31.19%), while hemoptysis (1.0%) was the least common. The associated comorbidities were hypertension (21.6%) and diabetes (10.0%). In terms of hematological parameters, lower total leukocyte counts were observed in 65% of cases and biochemical parameters, patients demonstrated elevated levels of albumin (53.72%), lactate dehydrogenase (45.71%), and natriuretic peptide (34.84%); however, total bilirubin was elevated in only 8% of cases. In the acute inflammatory cytokine profile, C-reactive protein (59.0%), tumor necrosis factor (58.0%), erythrocyte sedimentation rate (57.0%), interleukin-2 (IL-2, 54.0%), and IL-6 (52.0%) levels were increased, while prolactin levels (6.5%) were minimally elevated. The recovery rate was approximately 41%, and mortality was about 6.5%. The study also concluded that the clinical symptoms of COVID-19 were similar among pregnant and non-pregnant women. There was no evidence of vertical transmission of COVID-19 infection. This review critically analyzed COVID-19 as a public health hazard in order to help policy makers, health care givers, and primary physicians to promote early diagnosis and prevention.